Rachel Sherman's appointment as FDA deputy commissioner for medical products and tobacco, coming nearly a year after rumors surfaced she would get the job, puts her in a formal position to shepherd high-profile agency policies. Sherman is expected to steer efforts to overhaul combination product reviews, inject “big data” into regulatory decisions, adopt patient-centered approaches and increase coordination among the centers. Sherman formerly served as a medical policy director at FDA's drug center, before moving to the private sector to...